A committed oncology pharmacist, Sherif El-Refai works at Markey Cancer Center at University of Kentucky Hospital. In addition to handling those responsibilities, Sherif El-Refai is studying for his doctorate in pharmaceutical sciences at the University of Kentucky, where he also conducts lung cancer research.
Oncology pharmacists are professionals tasked with designing and implementing drug treatment plans specifically for patients with cancer. They perform a key role in caring for cancer by monitoring the dosing of powerful drugs, such as chemotherapy medications. They also interact with patients to ensure they understand the treatments administered to them.
These pharmacists have access to all information on cancer patients’ medications, including medications for other conditions they may have. They use that knowledge to alert patients to possible drug interactions that could lead to negative side effects. Additionally, some cancer patients struggle to remember to take their medications regularly, resulting in poor outcomes. Pharmacists support patients by providing checklists and other strategies to ensure timely dosing.
A graduate of the University of North Carolina with a PharmD, Sherif El-Refai also holds a master of business administration from the University of Florida. Sherif El-Rafai has leveraged his training to serve as an oncology pharmacist at the University of Kentucky Hospital’s Markey Cancer Center.
In addition to providing cancer care services, the Markey Cancer Center offers cancer screening. The only National Cancer Institute-designated center in Kentucky, the Markey Cancer Center collaborates with research groups and healthcare providers to improve cancer education and prevention across the state.
The center’s screening program tests for breast, lung, cervical, colorectal, skin, prostate, and ovarian cancers. The center advises individuals to talk to their physician regarding the appropriate age to begin screening, which varies according to each individual’s personal health and family history of cancer.
The Markey Cancer Center provides free screening for individuals who meet certain requirements. People who may qualify for free screening include those between the ages of 50 and 80, the uninsured or underinsured, and those with a household income less than 200 percent of Federal Poverty Guidelines.
Dr. Sherif El-Refai attended the University of North Carolina at Chapel Hill’s Eshelman School of Pharmacy, where he earned a doctor of pharmacy in 2011. While there, Dr. Sherif El-Refai also gained clerkship experience in the areas of ambulatory care, inpatient medicine, and ICU trauma.
Proclaimed by US News and World Report as the number one pharmacy school in the country, the Eshelman School of Pharmacy encompasses the Center for Nanotechnology in Drug Delivery (CNDD), researching new systems for medication delivery.
The CNDD is studying the effects of using sciences such as nanofabrication (creating devices that are measured in nanometers). One nanometer is equal to a millionth of a millimeter. Procedures like nanotoxicology or determining the health risks of nanomaterials to individuals are also being studied to produce safer and more efficient delivery systems for drugs. The CNDD hosts workshops and seminars regularly to discuss research and advancements in drug delivery systems, such as the annual Nanomedicine and Drug Delivery Symposium that drew more than 275 participants representing 11 different countries.
Sherif El-Refai is a doctoral student in clinical and experimental pharmaceutical science at the University of Kentucky. Sherif El-Refai works in the University’s Black Lab, where he contributes to research in genetic therapies for cancer.
In 2016, researchers at the Fred Hutchinson Cancer Research Center announced the development of a small device that could genetically modify a patient’s blood cells. Designed for use in places that have limited access to genetic cancer treatments, it fits on a table yet does the work of a high-budget clean room ordinarily available only in research hospitals.
The product is a redeveloped version of the closed-system CliniMACS Prodigy and follows current good manufacturing practices (cGMPs). Testing revealed that the quality of the modified blood cells was similar to or better than those created in regulated clean-room laboratories. Furthermore, testing in animal models demonstrated successful repopulation in two individual trials.
These positive results indicate the potential usefulness of the product in treating patients in remote areas. Researchers estimate the total per-patient cost of the system to be significantly less than that of the traditional model, thus making the system particularly promising for use in under-resourced communities.
As a doctoral student and part of the Black Lab at the University of Kentucky, Sherif El-Refai assists in research that develops cognitive cancer treatments. Sherif El-Refai, a student of clinical and experimental therapeutics, focuses particularly on cancers of the lung.
In October 2016, the U.S. Food and Drug Administration announced approval of a vaccine for lung cancer originally developed in Havana, Cuba. The vaccine is known as CIMAvax-EGF and will undergo testing in combination with Opdivo, an immunotherapy pharmaceutical that scientists believe may affect the vaccine’s effectiveness.
The vaccine has already received approval in several countries, where results show only a few months of added life expectancy for recipients. However, researchers at the Roswell Park Cancer Institute in Buffalo, New York, hope to find enough benefits to suggest the vaccine as a potential treatment for a disease that is difficult to treat.
The drug works to control cancer growth by targeting the epidermal growth factor protein, which drives cell growth. By stimulating the body to create antibodies that attack this protein, CIMAvax-EGF prevents it from promoting the growth of cancer cells. Although the results thus far are moderate, researchers hope that it may become an early tool for slowing cancer growth or for improving the quality of life for patients with later-stage tumors.
Dedicating his nearly 10-year career to the study and elimination of cancer, particularly lung cancer, Markey Cancer Center oncology pharmacist Sherif El-Refai conducts extensive research to assist in the development of successful medical care. Based in Lexington, Kentucky, Sherif El-Refai gained experience as a researcher at the laboratory of the University of Kansas College of Pharmacy.
According to a recent study conducted in the United States, as reported by Reuters Health, worsening depression symptoms are linked to a lower chance of survival for patients with lung cancer, especially so if in the early stages. The study found that when depression symptoms lifted, the chance for survival increased.
Lead author Donald R. Sullivan, a professor at Oregon Health and Science University, shared in the article via email that while this study does not prove causation, it does show the importance of not only treating the physical cancer, but to also screening for signs of depression in patients and treating depression as a means to help improve outcomes. Quality of life is impacted by the overall well-being of patients, which involves, among many other factors, their levels of depression.
Holding several advanced degrees in the area of pharmaceutical sciences, Sherif El-Refai has devoted nearly 10 years of study to the eradication of cancer. In addition to serving in the University of Kansas College of Pharmacy Black Lab, where he conducts lung cancer research to assist in developing more efficient treatments, Sherif El-Refai serves the Markey Cancer Center in the position of oncology pharmacist.
In the study of lung cancer, several subsets of the disease exist. Researchers say that because of the existence of these multiple subsets, the approach to treating the disease should vary for each patient based on which subset their cancer falls into.
Such findings came about as a result of a study recently published in the science journal Oncogene.
According to a press release, a group of University of Texas MD Anderson Cancer Center scientists examined data from more than 1,000 non-small-cell lung cancers, provided by the Cancer Genome Atlas, and organized them into specific classifications.
Senior author Chad Creighton shared that the different cancer subsets may respond differently to the same treatment. By knowing the makeup of each subset and how they react to each type of therapy, the research will aid in improving patient outcomes.